a Centre for Vaccines and Immunology, National Institute for Communicable Diseases, a division of the National Health Laboratory Service , Johannesburg , South Africa.
b Department of Health Sciences, University of Johannesburg , Johannesburg , South Africa.
Expert Rev Vaccines. 2019 Jul;18(7):751-754. doi: 10.1080/14760584.2019.1627878. Epub 2019 Jun 13.
: South Africa transitioned from using live-attenuated trivalent oral polio vaccine (tOPV), to a combination of tOPV and inactivated polio vaccine (IPV) in April 2009. We evaluated the immunogenicity of the South African combined tOPV-IPV schedule versus the tOPV-only schedule in South African infants. : Serum samples of HIV-unexposed infants were analysed retrospectively from two cohorts; infants enrolled from April 2005 through June 2006 and infants enrolled from December 2009 to April 2010. The primary vaccination series of the tOPV-only schedule included doses at birth, 6, 10 and 14 weeks, and the tOPV-IPV schedule included tOPV at birth and 6 weeks and IPV at 6, 10 and 14 weeks. Serum polio neutralising antibody titres to serotype-1, serotype-2 and serotype-3 were evaluated in infants at 18 weeks of age. : Infants who received the tOPV-IPV schedule had higher GMTs than infants who received tOPV-only for serotype-2 (9.63 vs. 8.80, P < 0.001) and serotype-3 (10.01 vs. 8.53, P < 0.001), as well as higher sero-protective titres for serotype-1 (100% vs. 96%, P = 0.014). : Our data support the option of the South African combined polio vaccination schedule as an immunogenic option for a combined schedule.
南非于 2009 年 4 月从使用口服脊髓灰质炎减毒活疫苗(tOPV)过渡到使用 tOPV 与灭活脊髓灰质炎疫苗(IPV)的联合疫苗。我们评估了南非联合使用 tOPV-IPV 疫苗接种程序与单独使用 tOPV 疫苗接种程序在南非婴儿中的免疫原性。
对两个队列中 HIV 未暴露婴儿的血清样本进行了回顾性分析;2005 年 4 月至 2006 年 6 月期间入组的婴儿和 2009 年 12 月至 2010 年 4 月期间入组的婴儿。单独使用 tOPV 疫苗接种程序的初级疫苗系列包括出生时、6 周、10 周和 14 周时接种 tOPV,而 tOPV-IPV 疫苗接种程序包括出生时和 6 周时接种 tOPV,以及 6 周、10 周和 14 周时接种 IPV。在婴儿 18 周龄时评估血清脊灰病毒中和抗体滴度针对血清型-1、血清型-2 和血清型-3。
接受 tOPV-IPV 疫苗接种程序的婴儿血清型-2(9.63 比 8.80,P<0.001)和血清型-3(10.01 比 8.53,P<0.001)的 GMT 均高于单独使用 tOPV 的婴儿,且血清型-1 的血清保护效力也更高(100%比 96%,P=0.014)。
我们的数据支持南非联合脊髓灰质炎疫苗接种方案作为联合疫苗接种方案的免疫原性选择。